Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Merck's Keytruda has failed 2 more Phase 3 trials.

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155000
(Total Views: 1163)
Posted On: 02/28/2023 12:40:59 PM
Posted By: Enjay
Merck's Keytruda has failed 2 more Phase 3 trials. I'll post the article and link below. Per their 12/31/22 10-K, Merck had $12.69B in cash and cash equivalents. They also have 6.5B authorized shares of stock vs. 3.5B issued. Keytruda sales were $20.9B in 2022 (35% of Merck's total worldwide sales). I can't remember the numbers, but months ago someone estimated potential Leronlimab sales based on the number of indications it would likely be approved for down the road. Keytruda sales should be a rough indication of that potential. I wonder if Merck has been kicking the tires as a possible oncology partner.




Merck’s Keytruda fails more prostate and lung cancer PhIII trials

Merck’s cancer drug behemoth, the anti-PD1 Keytruda, has failed two more Phase III trials in the hard-to-treat prostate cancer setting and in a certain lung cancer, per a Tuesday update.

That marks more than half a dozen Phase III flops in the past 12 months for the drug, which won its first approval in 2014 and has generated dozens of billions in revenue for Merck, accounting for $20.9 billion in global sales last year.

The drug, when combined with Pfizer and Astellas’ Xtandi and androgen deprivation therapy, did not show improvement compared to placebo plus those two drugs on radiographic progression-free survival or overall survival at an interim analysis in certain prostate cancer patients. With that, Merck is discontinuing KEYNOTE-641, the drugmaker said Tuesday.

It marks at least the fourth late-stage failure for Keytruda in various prostate cancer trials since last March. The latest comes in patients with metastatic castration-resistant prostate cancer.

“Merck is informing study investigators of the decision and advises patients in the study to speak to their physician regarding treatment,” the Big Pharma said of the discontinued trial.

The other setback came in metastatic nonsquamous non-small cell lung cancer. Patients had certain EGFR mutations and had previously received a tyrosine kinase inhibitor, including AstraZeneca’s Tagrisso.

A combo of Keytruda, pemetrexed and chemo did not beat out a regimen sans Keytruda on either primary endpoint of survival or survival without progression of disease for patients with that type of NSCLC in the Phase III known as KEYNOTE-789.

Eliav Barr, Merck Research Laboratories CMO and SVP of global clinical development, did not mince words in a press release, saying the drugmaker has “asked the tough questions in an effort to fully explore the potential” of Keytruda in search of helping “as many patients as possible.”

“Science is rarely a straight line, and while we are disappointed in these study results, our research to investigate KEYTRUDA in many difficult-to-treat types of cancer continues in earnest,” he said, thanking investigators and patients in the two trials.

Keytruda has not met the bar on multiple prostate cancer studies in the past 12 months, as well as trials investigating its use in certain cancers of the liver, head and neck. Merck has touted late-stage successes in that time, including HER2-negative adenocarcinoma in November and biliary tract cancer last month.

https://endpts.com/mercks-keytruda-fails-more...ii-trials/


(9)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us